Literature DB >> 25539862

Cell-density-dependent manifestation of partial characteristics for neuronal precursors in a newly established human gliosarcoma cell line.

Pei-Sen Yao1, De-Zhi Kang, Xing-Fu Wang, Ru-Ying Lin, Zu-Cheng Ye.   

Abstract

Gliosarcoma cell line K308 was established from a primary tumor specimen removed from a 51-year-old male Han Chinese patient. Besides the typical characteristics of gliosarcoma cells, K308 cells express abundant glutaminase and can release large amount of glutamate. K308 exhibited cell-density-dependent expression of neuronal precursor markers, particularly nestin. At low density, the majority of K308 cells were nestin negative (approximately 70%) and nestin levels remained homogenous within each single-cell-derived colony when K308 proliferated. After reaching confluence, however, the majority of K308 cells turned nestin positive. These confluent K308 cells were also Sox2 positive and could form tumor spheres even in serum-containing media.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25539862     DOI: 10.1007/s11626-014-9839-x

Source DB:  PubMed          Journal:  In Vitro Cell Dev Biol Anim        ISSN: 1071-2690            Impact factor:   2.416


  23 in total

1.  Nestin expression in high-grade osteosarcomas and its clinical significance.

Authors:  Iva Zambo; Marketa Hermanova; Dagmar Adamkova Krakorova; Peter Mudry; Karel Zitterbart; Michal Kyr; Karel Vesely; Jaroslav Sterba; Renata Veselska
Journal:  Oncol Rep       Date:  2012-02-14       Impact factor: 3.906

Review 2.  The pathogenesis of tumour associated epilepsy.

Authors:  A Beaumont; I R Whittle
Journal:  Acta Neurochir (Wien)       Date:  2000       Impact factor: 2.216

3.  Establishment and characterization of a cell line from a human gliosarcoma.

Authors:  J T Rutka; J R Giblin; H K Høifødt; D V Dougherty; C W Bell; J R McCulloch; R L Davis; C B Wilson; M L Rosenblum
Journal:  Cancer Res       Date:  1986-11       Impact factor: 12.701

Review 4.  Roles of glutamine synthetase inhibition in epilepsy.

Authors:  Tore Eid; Kevin Behar; Ronnie Dhaher; Argyle V Bumanglag; Tih-Shih W Lee
Journal:  Neurochem Res       Date:  2012-04-10       Impact factor: 3.996

5.  Gliosarcoma with chondroid and osseous differentiation.

Authors:  Jens Schittenhelm; Torsten Erdmann; Stefan Maennlin; Bernd E Will; Rudi Beschorner; Antje Bornemann; Richard Meyermann; Michel Mittelbronn
Journal:  Neuropathology       Date:  2007-02       Impact factor: 1.906

6.  Gliosarcoma: an immunohistochemical study.

Authors:  J W Grant; P V Steart; A Aguzzi; D B Jones; P J Gallagher
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

7.  Mixed glioblastoma multiforme and sarcoma. A clinicopathologic study of 26 radiation therapy oncology group cases.

Authors:  J M Meis; K L Martz; J S Nelson
Journal:  Cancer       Date:  1991-05-01       Impact factor: 6.860

Review 8.  Secondary gliosarcoma: a review of clinical features and pathological diagnosis.

Authors:  Seunggu J Han; Isaac Yang; Tarik Tihan; Susan M Chang; Andrew T Parsa
Journal:  J Neurosurg       Date:  2010-01       Impact factor: 5.115

Review 9.  Gliosarcoma with multiple extracranial metastases: case report and review of the literature.

Authors:  Thomas L Beaumont; William J Kupsky; Geoffrey R Barger; Andrew E Sloan
Journal:  J Neurooncol       Date:  2006-12-14       Impact factor: 4.506

Review 10.  Chemoresistance of glioblastoma cancer stem cells--much more complex than expected.

Authors:  Dagmar Beier; Joerg B Schulz; Christoph P Beier
Journal:  Mol Cancer       Date:  2011-10-11       Impact factor: 27.401

View more
  2 in total

1.  Density-Dependent Regulation of Glioma Cell Proliferation and Invasion Mediated by miR-9.

Authors:  Mark Katakowski; Nicholas Charteris; Michael Chopp; Evgeniy Khain
Journal:  Cancer Microenviron       Date:  2016-12-14

2.  Establishment and characteristics of GWH04, a new primary human glioblastoma cell line.

Authors:  Fangling Cheng; Xueyan Wan; Baofeng Wang; Youwei Li; Peng Peng; Sanpeng Xu; Chao Han; Feng Mao; Dongsheng Guo
Journal:  Int J Oncol       Date:  2022-09-28       Impact factor: 5.884

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.